التفاصيل البيبلوغرافية
| العنوان: |
CCTG LY18‐A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma ‐ the RGDP‐Venetoclax substudy. |
| المؤلفون: |
Assouline, S., Villa, D., Hay, A., Johnson, N., Crump, M., Kridel, R., Prica, A., Shamy, A., Gerrie, A., Savage, K., Kelly, J., Shepherd, L., Chen, B., Kuruvilla, J., Manji, F. |
| المصدر: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p589-590, 2p |
| مصطلحات موضوعية: |
LYMPHOMAS, B cell lymphoma |
| مستخلص: |
B Introduction: b Therapies for relapsed/refractory (r/r) large B cell lymphomas are expanding. RGDP (rituximab, gemcitabine, dexamethasone, cisplatin) plus venetoclax (RGDP-V) was evaluated in adult pts with diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, transformed follicular lymphoma, or high-grade B cell lymphoma after one prior line of therapy. CCTG LY18-A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma - the RGDP-Venetoclax substudy. [Extracted from the article] |
|
Copyright of Hematological Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder